effect overlay
activetrials

Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer’s Disease
 

HREC: 2021.066
Principal Investigator: Prof Amy Brodtmann
Coordinator contact: Sophie Robinson
Funding: Commercial

A Randomized, Placebo-Controlled, Double-Blind Study of XPro™ in Patients with Mild Alzheimer’s Disease with Biomarkers of Inflammation
 

HREC: 2022.142
Principal Investigator: Dr Christopher Kyndt
Coordinator contact: Sophie Robinson
Funding: Commercial
Dementia

A Phase 3b/4 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Verify the Clinical Benefit of Aducanumab (BIIB037) in Participants with Alzheimer’s Disease
 

HREC: 2022.207
Principal Investigator: A/Prof David Darby
Coordinator contact: Lauren Martell
Funding: Commercial
Dementia

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 52-Week Study Evaluating the Safety and Efficacy of Simufilam 100 Mg Tablets in Subjects With Mild-to-Moderate Alzheimer’s Disease
 

HREC: 2022.215
Principal Investigator: Dr Christopher Kyndt
Coordinator contact: Lesley-Anne Attard
Funding: Commercial
Epilepsy

Psychological and cultural aspects of psychogenic non-epileptic seizures (PNES)
 

HREC: 2012.030
Principal Investigator: Prof Terry O'Brien
Coordinator contact:
Funding: Non-Commercial